DrugBank ID
stringlengths 7
7
| Accession Numbers
stringlengths 7
102
⌀ | Common name
stringlengths 3
226
| CAS
stringlengths 7
12
⌀ | UNII
stringlengths 10
10
⌀ | Synonyms
stringlengths 2
1.48k
⌀ | Standard InChI Key
stringlengths 27
27
⌀ |
|---|---|---|---|---|---|---|
DB17091
| null |
Davesomeran
|
2798905-80-1
|
TYF7YW7ENF
| null | null |
DB17092
| null |
Norclobazam
|
22316-55-8
| null |
1h-1,5-benzodiazepine-2,4(3h,5h)-dione, 8-chloro-1-phenyl-7-chloro-5-phenyl-1,2,4,5-tetrahydro-3h-1,5-benzodiazepine-2,4-dione | Clobazam metabolite m9 | Desmethylclobazam | N-desmethylclobazam
| null |
DB17093
| null |
P140K methylguanine-DNA-methyltransferase mutant CD34+ cells
| null | null | null | null |
DB17094
| null |
MK-7288
|
936626-07-2
|
19EF2T21ST
|
MK-7288 free base | Spiro(cyclohexane-1,5'(7'h)-furo(3,4-b)pyridine)-4-carboxamide, 2'-methoxy-n-methyl-7'-oxo-n-(2-(1-piperidinyl)ethyl)-, trans-
|
QTAKNJDNFNDYPP-CIEDQVTBSA-N
|
DB17095
| null |
Riltozinameran
|
2749948-25-0
|
72JR7XDV94
| null | null |
DB17096
| null |
UCB7362
| null | null | null |
AWSRDDSRQUJMAJ-LCAJTWGOSA-N
|
DB17097
| null |
Vorasidenib
|
1644545-52-7
|
789Q85GA8P
|
1,3,5-triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-n2,n4-bis((1r)-2,2,2-trifluoro-1-methylethyl)- | Vorasidenib
|
QCZAWDGAVJMPTA-RNFRBKRXSA-N
|
DB17098
| null |
Virulizin
|
216586-46-8
|
E5SF1Z7U1S
|
Bos taurus bile extract (heat hydrolyzed; mw < 3000) | Bos taurus bile immunomodulator | Bovine bile extract (heat hydrolyzed; mw < 3000) | Bovine bile immunomodulator | Glicofosamina | Immunomodulator extracted from bovine bile | Macrophage activator extracted from bovine bile | Virulizin-2.gamma.
| null |
DB17099
| null |
SY-5609
|
2417302-07-7
|
TW6044C3O6
|
(S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile | 1H-Indole-6-carbonitrile, 7-(dimethylphosphinyl)-3-[2-[[(3S)-6,6-dimethyl-3-piperidinyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]- | SY 5609 | SY5609
|
JDJOUBVVSQDIRC-AWEZNQCLSA-N
|
DB17100
| null |
NEO-212
|
1361198-79-9
|
237TB781D9
|
(s)-perillyl alcohol temozolomide carbamate | Carbamic acid, n-((3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazin-8-yl)carbonyl)-, ((4s)-4-(1-methylethenyl)-1-cyclohexen-1-yl)methyl ester | Tmz-poh carbamate
|
MGTLGARADRIKNV-GFCCVEGCSA-N
|
DB17101
| null |
SC 41930
|
120072-59-5
|
EVH7O0422T
|
(+/-)-7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2h-1-benzopyran-2-carboxylic acid | 2h-1-benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl- | 7-(3-(4-acetyl-3-methoxy-2-propyl-phenoxy)propoxyl-3,4-dihydro-8-propyl-2h-1-benzopyran-2-carboxylic acid
|
ZVVCSBSDFGYRCB-UHFFFAOYSA-N
|
DB17102
| null |
Ioflubenzamide I-131
|
1214283-52-9
|
65O1D58Z6V
|
(131i)-n-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide | [131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide | Benzamide, n-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-(iodo-131i)-2-methoxy- | Ioflubenzamide (131 i) | Ioflubenzamide (131i) | Ioflubenzamide i 131 | Ioflubenzamide, I-131 | N-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-((sup 131)i)iodo-2-methoxybenzamide | N-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-(iodo-131i)-2-methoxybenzamide
|
UPRRZQGAQRAODM-AWUWEVMDSA-N
|
DB17103
| null |
Solasonine
|
19121-58-5
|
TR60638HXL
|
alpha-Solasonine | Purapurine | Solasonin | Tomatine solaradixine
|
QCTMYNGDIBTNSK-XEAAVONHSA-N
|
DB17104
| null |
BG-P400-TAT
| null |
70JCV6CT08
|
[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid | 2-[4-[4-[[1-[2-[2-[2-[2-[2-[2-[2-[4-[(Diaminomethylideneamino)methyl]phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methoxy]-3,5-diiodophenoxy]-3,5-diiodophenyl]acetic acid
|
DVWARFPIVDNTDK-UHFFFAOYSA-N
|
DB17105
| null |
Venadaparib
|
1681017-83-3
|
PUP792O0IW
|
1(2h)-phthalazinone, 4-((3-((3-((cyclopropylamino)methyl)-1-azetidinyl)carbonyl)-4-fluorophenyl)methyl)- | 4-((3-((3-((cyclopropylamino)methyl)-1-azetidinyl)carbonyl)-4-fluorophenyl)methyl)-1(2h)-phthalazinone
|
YNBQAYKYNYRCCA-UHFFFAOYSA-N
|
DB17106
| null |
SYD-003
|
249937-52-8
|
TE3ESF890C
|
(5-amino-1-(4-fluoro-phenyl)-1h-pyrazol-4-yl)-(3-(2,3-dihydroxy-propoxy)-phenyl)-methanone | [5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone | Methanone, (5-amino-1-(4-fluorophenyl)-1h-pyrazol-4-yl)(3-(2,3-dihydroxypropoxy)phenyl)-
|
IJDQETGUEUJVTB-UHFFFAOYSA-N
|
DB17107
| null |
Lifileucel
|
2306267-74-1
|
R0835E18NH
|
Autologous tumor infiltrating lymphocytes | Lifileucel | Tumor infiltrating lymphocytes, autologous
| null |
DB17108
| null |
(1-Hydroxy-2-oxopiperidin-3-yl)phosphonic acid
|
2004714-32-1
|
64T5RTG4MY
|
Phosphonic acid, p-(1-hydroxy-2-oxo-3-piperidinyl)-
|
DVZQUMSQEGOYMX-UHFFFAOYSA-N
|
DB17109
| null |
Tegavivint
|
1227637-23-1
|
18AP231HUP
|
9,10-anthracenedione, 2,7-bis(((3r,5s)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel- | Tegavivint
|
GAPRVZKWPDRAJA-TVRZPQSBSA-N
|
DB17110
| null |
NRC-AN-019
|
879507-25-2
|
K6W49JL148
|
(3,5-BIS TRIFLUOROMETHYL)-N-(4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2-YL AMINO) PHENYL)BENZAMIDE | (3,5-Bis Trifluoromethyl)-N-[4-Methyl-3-(4-Pyridin-3Yl-Pyrimidin-2-Yl Amino) Phenyl] Benzamide | 3,5-BIS(TRIFLUOROMETHYL)-N-(4-METHYL-3-((4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)AMINO)PHENYL)BENZAMIDE | BDBM111455
| null |
DB17111
| null |
Dimethylaminomicheliolide
|
1403357-81-2
|
580BNQ45EO
|
11.BETA.,13-DIHYDRO-13-(DIMETHYLAMINO)MICHELIOLIDE | AZULENO(4,5-B)FURAN-2(3H)-ONE, 3-((DIMETHYLAMINO)METHYL)-3A,4,5,7,8,9,9A,9B-OCTAHYDRO-9-HYDROXY-6,9-DIMETHYL-, (3R,3AS,9R,9AS,9BS)-
|
ZPBIJIIQXPRJSS-WNZSCWOMSA-N
|
DB17112
| null |
SM-337
|
1071992-61-4
| null | null | null |
DB17113
| null |
Folitixorin
|
3432-99-3
|
0SXY5ET48B
|
5,10-methylene-(6rs)-tetrahydrofolic acid | 5,10-methylene-5,6,7,8-tetrahydrofolic acid | 5,10-methylenetetrafolate | 5,10-methylenetetrahydrofolic acid | Folic acid, tetrahydro-n5,n10-methylene- | L-glutamic acid, n-(4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9h)-yl)benzoyl)- | N5,n10-methylene-5,6,7,8-tetrahydrofolic acid | N5,n10-methylenetetrahydrofolic acid | N5,n10-methylenetetrahydropteroylglutamic acid
|
QYNUQALWYRSVHF-ABLWVSNPSA-N
|
DB17114
| null |
CT-179
|
1996636-69-1
|
4Z0F3ZM8ZD
|
1-(2-(3-(3,4-dichlorophenyl)ureido)-6-methyl-pyrimidin-4-yl)-amino-3(dimethylamino)propane | CT 179 | CT179 | Urea, n-(3,4-dichlorophenyl)-n'-(4-((3-(dimethylamino)propyl)amino)-6-methyl-2-pyrimidinyl)-
|
MWEZWAONAIZIAQ-UHFFFAOYSA-N
|
DB17115
| null |
AB-8939
|
1974336-09-8
|
REU6L9A46J
|
1-(4-(2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl)-phenyl)-imidazolidin-2-one | 2-imidazolidinone, 1-(4-(2-((5-(ethoxymethyl)-2-methylphenyl)amino)-5-oxazolyl)phenyl)-
|
ZBAFYGYLXHEICJ-UHFFFAOYSA-N
|
DB17116
| null |
Ontorpacept
|
2131089-46-6
|
Q8A4U1Z9N2
|
1-118-signal regulatory protein .alpha. (human) fusion protein with immunoglobulin g1 (human fc fragment), dimer
| null |
DB17117
| null |
Seclidemstat
|
1423715-37-0
|
TYH386V3WJ
|
Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2e)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide | N'-[(1E)-1-(5-chloro-2-hydroxyphenyl)ethylidene]- 3-(4-methylpiperazine-1-sulfonyl)benzohydrazide
|
MVSQDUZRRVBYLA-HYARGMPZSA-N
|
DB17118
| null |
Ivaltinostat
|
936221-33-9
| null |
(E)-N-(3-(DIMETHYLAMINO)PROPYL)-N'-HYDROXY-2-((1-NAPHTHYLOXY)METHYL)-2-OCTENEDIAMIDE | 2-OCTENEDIAMIDE, N1-(3-(DIMETHYLAMINO)PROPYL)-N8-HYDROXY-2-((1-NAPHTHALENYLOXY)METHYL)-, (2E)-
|
UOKSXAOZBSWROR-DOELHFPHSA-N
|
DB17119
| null |
BDBM249432
| null | null | null | null |
DB17120
| null |
Imifoplatin
|
1339960-28-9
|
F5I3T42BXC
|
(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II) | 1,2-cyclohexanediamine pyrophosphatoplatinum(ii), (r,r)- | Cyclohexane-(1r,2r)-diamineplatinum(ii) diphosphate | Cyclohexanediamine pyrophosphatoplatinum(ii), (1r,2r)- | Dihydrogen (sp-4-2)-((1r,2r)-cyclohexane-1,2-diamine-.kappa.2n1,n2)(diphosphato(4)-.kappa.2o1,o3)platinate(2) | Platinate(2-), ((1r,2r)-1,2-cyclohexanediamine-.kappa.n1,.kappa.n2)(diphosphato(4-)-.kappa.o,.kappa.o'')-, hydrogen (1:2), (sp-4-2)-
|
SCMHTXQHAHWVSX-BNTLRKBRSA-L
|
DB17121
| null |
IM-156 free base
|
1422365-93-2
|
4G3BUV6ZSK
|
1-pyrrolidinecarboximidamide, n-(imino((4-(trifluoromethoxy)phenyl)amino)methyl)- | 1-Pyrrolidinecarboximidamide, N-[imino[[4-(trifluoromethoxy)phenyl]amino]methyl]- | Hl-156a free base | Hl156a free base | Im156 free base | N-(imino((4-(trifluoromethoxy)phenyl)amino)methyl)-1-pyrrolidinecarboximidamide | N-[Imino[[4-(trifluoromethoxy)phenyl]amino]methyl]-1-pyrrolidinecarboximidamide
|
NGFUHJWVBKTNOE-UHFFFAOYSA-N
|
DB17122
| null |
OSE-2101
| null | null |
10 synthetic peptides targeting 5 tumor associated antigens
| null |
DB17123
| null |
TG01 vaccine
| null | null |
12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)
| null |
DB17124
| null |
Omburtamab I-131
| null |
B6PMV8U3C4
|
131-I-8H9 monoclonal antibody | 131I-burtomab | 131I-omburtamab | Burtomab I-131 | Iodine (131I) omburtamab
| null |
DB17125
| null |
BGA002
| null | null |
16 base single stranded peptide nucleic acid oligonucleotide - 7 aminoacids peptide
| null |
DB17126
| null |
SRX-1177
| null | null |
177-LU-DOTA-GlyGlyNle-CycMSHhex | 177Lu-DOTA-GGNle-CycMSH(hex)
| null |
DB17127
| null |
Iopofosine I-124
|
873438-87-0
|
08W354EC17
|
18-(p-(124i )-iodophenyl)octadecyl phosphocholine | Ethanaminium, 2-((hydroxy((18-(4-(iodo-124i)phenyl)octadecyl)oxy)phosphinyl)oxy)-n,n,n-trimethyl-, inner salt
|
ZOAIEFWMQLYMTF-PEHXSSJGSA-N
|
DB17128
| null |
M-(18F)-fluorobenzylguanidine
|
156021-12-4
|
CD7WXM716P
|
18F-meta-fluorobenzylguanidine | Guanidine, ((3-(fluoro-18f)phenyl)methyl)- | Meta-fluoro benzylguanidine F-18
|
HNPHEZIYSZIWHH-RVRFMXCPSA-N
|
DB17129
| null |
Pelabresib anhydrous
|
1380087-89-7
|
U4017GUQ06
|
2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-isoxazolo(5,4-d)(2)benzazepin-4-yl)acetamide | 4h-isoxazolo(5,4-d)(2)benzazepine-4-acetamide, 6-(4-chlorophenyl)-1-methyl-, (4s) | CPI-0610 anhydrous | Pelabresib
|
GCWIQUVXWZWCLE-INIZCTEOSA-N
|
DB17130
| null |
Spanlecortemlocel
| null |
D8O38M043D
|
Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and CD34 depleted) derived from the same UCB unit | ALLOGENEIC UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC STEM AND PROGENITOR CELLS MGTA-456 | EXPANDED UMBILICAL CORD BLOOD PRODUCT HSC835 | Spanlecortemlocel
| null |
DB17131
| null |
JAB-3068
| null |
V6Q7413SA8
|
JAB3068
|
HGYTYZKWKUXRKA-MRXNPFEDSA-N
|
DB17132
| null |
Omidubicel
| null |
ET4JC4S66E
|
Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF) | NiCord | Omidubicel | Omidubicel-onlv
| null |
DB17133
| null |
ADH-503
|
2055362-74-6
|
THN3VQ67CA
|
2-Hydroxy-N,N,N-trimethylethanaminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate
| null |
DB17134
| null |
Methyl bacteriopurpurinimide
|
2044523-17-1
|
E7DBJ0SBC7
|
3-(1-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester | 9,12-imino-2,21-metheno-7,4:14,17-dinitrilo-4h-pyrido(4,3-b)azacyclononadecine-16-propanoic acid, 10-(1-butoxyethyl)-19-butyl-5-ethyl-1,5,6,15,16,18,19,20-octahydro-6,11,15,22-tetramethyl-18,20-dioxo-, (5r,6r,15s,16s)- | Bacteriopurpurinimide-methyl ester | Photobac
|
PPYDAYHKDYWTBT-JBKJMLRISA-N
|
DB17135
| null |
Bromopyruvate
|
1113-59-3
|
63JMV04GRK
|
3-bromo-2-oxopropanoic acid | 3-bromopyruvate | 3-bromopyruvic acid | Bromopyruvic acid | β-Bromopyruvic acid
|
PRRZDZJYSJLDBS-UHFFFAOYSA-N
|
DB17136
| null |
MPT-0L055
|
2069950-14-5
|
U1DMN1EU6W
|
4-(((3-chloro-1,4-dihydro-1,4-dioxo-2-naphthalenyl)amino)methyl)-n-3-pyridinylbenzamide | 4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-n-(pyridine-3-yl)benzamide | Benzamide, 4-(((3-chloro-1,4-dihydro-1,4-dioxo-2-naphthalenyl)amino)methyl)-n-3-pyridinyl-
|
WCXAUCDLLSWGQS-UHFFFAOYSA-N
|
DB17137
| null |
4-Iodophenylalanine I-131
|
76641-05-9
|
606VTF676Y
|
4-(131i)iodo-l-phenylalanine | 4-iodo-l-phenylalanine-131i | L-phenylalanine, 4-(iodo-131i)-
|
PZNQZSRPDOEBMS-WPUCPVGPSA-N
|
DB17138
| null |
4-(2-(3-Propyl-(1,2,4)oxadiazol-5-yl)-vinyl)-benzene-1,2-diol
|
1332498-21-1
|
ZGL5E40F57
| null |
MAWOOXDYMFRJNN-FNORWQNLSA-N
|
DB17139
| null |
MB07133
|
685111-92-6
|
BNL5ERR07R
|
(2R,4S)-4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)-beta-d-arabinofuranosyl)-2(1H)-pyrimidinone | 2(1h)-pyrimidinone, 4-amino-1-(5-o-((2r,4s)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl)-.beta.-d-arabinofuranosyl)- | 4-amino-1-(5-o-((2r, 4s)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl)-.beta.-d-arabinofuranosyl)-2(1h)-pyrimidinone | 4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone
|
HOAHIHGOMCBTFW-XCJSNOFESA-N
|
DB17140
| null |
JNJ-28312141
|
885692-52-4
|
YKQ241VJ92
|
1h-imidazole-2-carboxamide, 5-cyano-n-(2-(1-cyclohexen-1-yl)-4-(1-(2-(dimethylamino)acetyl)-4-piperidinyl)phenyl)- | 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide
|
GUBJNPWVIUFSTR-UHFFFAOYSA-N
|
DB17141
| null |
Vodobatinib
|
1388803-90-4
|
N8Q12KU2SW
|
2-chloro-6-methyl-n'-(4-methyl-3-(2-(quinolin-3-yl)ethynyl)benzoyl)benzohydrazide | 4-methyl-3-quinolin-3-yl-ethynyl benzoic acid n'-(2-chloro-6-methylbenzoyl)hydrazide | 4-methyl-3-quinolin-3-ylethynylbenzoic acid n'-(2-chloro-6-methylbenzoyl) hydrazide | Benzoic acid, 2-chloro-6-methyl-, 2-(4-methyl-3-(2-(3-quinolinyl)ethynyl)benzoyl)hydrazide
|
ZQOBVMHBVWNVBG-UHFFFAOYSA-N
|
DB17142
| null |
LPT-99
|
1263477-83-3
|
A2Y8E9P363
|
2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-n-(2-(5-methoxy-1h-indol-3-yl)ethyl) acetamide | 2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-n-(2-(5-methoxy-1h-indol-3-yl)ethyl)acetamide | 2-piperazineacetamide, 4-(2-(2,4-dichlorophenyl)ethyl)-n-(2-(5-methoxy-1h-indol-3-yl)ethyl)-3,6-dioxo-1-(2-(2-thienyl)ethyl)-
|
XLXXBYJYWULGGD-UHFFFAOYSA-N
|
DB17143
| null |
APTO-253
|
916151-99-0
|
WB59MRW00U
|
1h-imidazo(4,5-f)(1,10)phenanthroline, 2-(5-fluoro-2-methyl-1h-indol-3-yl)- | 2-(5-fluoro-2-methyl-1h-indol-3-yl)-1h-imidazo(4,5-f)(1,10)phenanthroline | 2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline | Lor-253(former code) | Lt-253(former code)
|
NIRXBXIPHUTNNI-UHFFFAOYSA-N
|
DB17144
| null |
Lansoprazole sulfone
|
131926-99-3
| null |
1h-benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfonyl)- | Lansoprazole impurity b | Lansoprazole related compound a
| null |
DB17145
| null |
IT-139
|
197723-00-5
|
7OSJ9KS483
|
Ruthenate(1-), tetrachlorobis(1h-indazole-.kappa.n2)-, sodium (1:1), (oc-6-11)- | Sodium hydride; tetrachloro-bis(1h-indazol-2-yl)ruthenium | Sodium Trans-[Tetrachlorobis(1H-Indazole)Ruthenate(iii)]
|
YGDDGJPSWMFECS-UHFFFAOYSA-J
|
DB17146
| null |
Abequolixron
|
610318-54-2
|
Q26B92650V
|
(3-((3r)-3-(((2-chloro-3-(trifluoromethyl)phenyl)methyl)(2,2- diphenylethyl)amino)butoxy)phenyl)acetic acid | 2-(3-((3r)-3-(((2-chloro-3-(trifluoromethyl)phenyl)methyl)(2,2-diphenylethyl)amino)butoxy)phenyl)acetic acid | 2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid | Benzeneacetic acid, 3-((3r)-3-(((2-chloro-3-(trifluoromethyl)phenyl)methyl)(2,2-diphenylethyl)amino)butoxy)-
|
ZLJZDYOBXVOTSA-XMMPIXPASA-N
|
DB17147
| null |
Methionine C-11
|
60305-58-0
|
ED857BWP29
|
11c-methionine | 2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine | L-(s-methyl-11c)methionine | L-11c-methylmethionine | L-methionine ((11c)methyl) | Methionine (11c)
|
FFEARJCKVFRZRR-JJZBXVGDSA-N
|
DB17148
| null |
TH-9402 free base
|
1373958-68-9
|
934QHK1OOK
|
4,5 dibromorhodamine methyl ester | 4,5-dibromorhodamine 123 free base | 4,5-dibromorhodamine methyl ester | Benzoic acid, 2-(6-amino-4,5-dibromo-3-imino-3h-xanthen-9-yl)-, methyl ester
|
QDBPSMVYZMGGGG-UHFFFAOYSA-N
|
DB17149
| null |
Berubicin
|
677017-23-1
|
6QPN83HK2M
|
(8s,10s)-10-((3-amino-4-o-benzyl-2,3,6-trideoxy-a-l-lyxo-hexopyranosyl)oxy)-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione | 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-o-(phenylmethyl)-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s,10s)-
|
FIGNGSHKNAHTSH-JJMFXPFOSA-N
|
DB17150
| null |
Ukrain cation
|
732958-87-1
|
53F09PQ5P5
|
(1,3)benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridinium, 13,13',13''-(phosphinothioylidynetris(imino-2,1-ethanediyl))tris(5b,6,7,12b,13,14-hexahydro-6-hydroxy-13-methyl-, (5br,5'br,5''br,6s,6's,6''s,12bs,12'bs,12''bs)- | Chelidoninium, 5,5',5''-(phosphinothioylidynetris(imino-2,1-ethanediyl))tris(5-methyl-
|
DZWOYVBKCHRHGV-OZLOOOLJSA-N
|
DB17151
| null |
5,6-dihydro-5-azacytidine
|
62488-57-7
|
0627D8VG1C
|
1,3,5-triazin-2(1h)-one, 4-amino-5,6-dihydro-1-.beta.-d-ribofuranosyl-
|
LJIRBXZDQGQUOO-KVTDHHQDSA-N
|
DB17152
| null |
DRF-1042
|
200619-13-2
|
461WVF206P
|
1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-, (4s)- | 5-(2'-hydroxyethoxy)-20(s)-camptothecin
|
XAKLYHGHEFMDAP-IAXKEJLGSA-N
|
DB17153
| null |
Roneparstat
|
1407492-04-9
|
1J0593208B
|
Roneparstat
| null |
DB17154
| null |
Rosomidnar
|
871597-03-4
|
2X4LQG2T5U
|
(3'-5')d(c-a-c-g-c-a-c-g-c-g-c-a-t-c-c-c-c-g-c-c-c-g-t-g) | Rosomidnar
| null |
DB17155
| null |
BPR-0L075
|
613679-11-1
|
W918223VQ6
|
6-methoxy-3-(3,4,5-trimethoxybenzoyl) indole | Methanone, (6-methoxy-1h-indol-3-yl)(3,4,5-trimethoxyphenyl)-
|
UZJVBXKFBQNDTQ-UHFFFAOYSA-N
|
DB17156
| null |
RP-72
| null | null |
72 amino acid proprietary recombinant protein antagonist for the CXCR1 and CXCR2 receptors of interleukin-8 | CXC chemokine receptor types 1 and 2 inhibitor RP72 | Rise Prot-72
| null |
DB17157
| null |
Darleukin
| null |
2OQ3OPV2F8
|
Daromun component L19IL2 | L19-IL2 | L19-IL2 Monoclonal antibody-cytokine fusion protein | L19IL2
| null |
DB17158
| null |
Satoreotide trizoxetan
|
1638746-88-9
|
3M7TX701A4
| null |
MDDXVKPIPNUPBG-LJLVINLTSA-N
|
DB17159
| null |
Denfivontinib
|
1457983-28-6
|
B06W426B66
|
8-Bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido[4,3-D]pyrimidin-5(6H)-one | 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one | G-749
|
SXWMIXPJPNCXQQ-UHFFFAOYSA-N
|
DB17160
| null |
Edotreotide yttrium Y-90
|
322407-70-5
|
ABF7OG3FA3
|
90y-dota-tyr3-octreotide | 90y-dotatoc | 90ydotatoc | Dotatoc yttrium Y-90 | Edotreotide 90y chelate | Y-90 dota-tyr(3)-octreotide | Yttrium (90y) edotreotide | Yttrium y 90-dota-tyr3-octreotide | Yttrium y 90-edotreotide | Yttrium Y-90 n-((4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl)-d-phe-cys-tyr-d-trp-lys-thr-cys-thr (2-7)disulfide
|
DUSFGVAHRFYHFD-LONMIUDCSA-K
|
DB17161
| null |
99mTc-HYNIC (Tyr3)-octreotide
|
913556-61-3
|
534I87AT7J
|
99mtc-ethylenediamine n,n'-diacetic acid/hydrazinonicotinamide-tyr3-octreotide | 99mTc-HYNIC-[D-Phe1,Tyr3-Octreotide] | 99mTc-Hynic-TOC | 99mTcEDDA/HYNIC-TOC | Hynic (tyr3)-octreotide technetium tc-99m
|
LGXRRVXXRJRTHK-HWLOXKIFSA-I
|
DB17162
| null |
ATG-101
| null | null |
PD-L1/4-1BB bispecific antibody
| null |
DB17163
| null |
Senaparib
|
1401682-78-7
|
MNZ4OP95CF
|
2,4(1h,3h)-quinazolinedione, 5-fluoro-1-((4-fluoro-3-((4-(2-pyrimidinyl)-1-piperazinyl)carbonyl)phenyl)methyl)- | 5-fluoro-1-((4-fluoro-3-((4-(2-pyrimidinyl)-1-piperazinyl)carbonyl)phenyl)methyl)-2,4(1h,3h)-quinazolinedione
|
VBTUJTGLLREMNW-UHFFFAOYSA-N
|
DB17164
| null |
ZB131
| null | null | null | null |
DB17165
| null |
KT-333
| null | null | null | null |
DB17166
| null |
Tapotoclax
|
1883727-34-1
|
97W7N9T08G
|
MCL-1 inhibitor AMG 176 | MCL-1 inhibitor AMG-176
|
JQNINBDKGLWYMU-GEAQBIRJSA-N
|
DB17167
| null |
Phenylacetylglutamine
|
28047-15-6
| null |
Antineoplaston as 2-1 component phenylacetylglutamine | Antineoplaston as2-1 component phenylacetylglutamine | Astugenal component phenylacetylglutamine | L-glutamine, n2-(phenylacetyl)- | Phenylacetyl-l-glutamine
| null |
DB17168
| null |
TPI-287
|
849213-15-6
|
A2VM2V569A
|
(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane | TPI-287
|
FDTAUJJRHBRHIJ-FDJAAIFISA-N
|
DB17169
| null |
MTI-201
| null | null |
MTI 201 | MTI201
| null |
DB17170
| null |
WSD-0922
|
2226552-64-1
|
UF6QZ5E1AY
|
(r)-6-((3,3-difluoro-1-methylpiperidin-4-yl)oxy)-n-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine-
|
RIHUDRGMCALEAK-HXUWFJFHSA-N
|
DB17171
| null |
Ziftomenib
|
2134675-36-6
|
4MOD1F4ENC
|
(s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile | 1h-indole-2-carbonitrile, 4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)-1-piperidinyl)methyl)-1-((2s)-2-(4-(methylsulfonyl)-1-piperazinyl)propyl)- | Menin-mll interaction inhibitor ko 539
|
BGGALFIXXQOTPY-NRFANRHFSA-N
|
DB17172
| null |
Activated natural killer cell therapy
| null | null |
activated natural killer[aNK] | aNK cells | Neukoplast | NK-92 cells
| null |
DB17173
| null |
ONCOS‐102
| null | null |
Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus
| null |
DB17174
| null |
Diaziquone
|
57998-68-2
|
FQL5EUP13W
|
Aziridinyl benzoquinone | AZQ | Carbamic acid, (2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl)bis-, diethyl ester | Diaziquone | Diethyl 2,5-bis-(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamate | NSC-182986
|
WVYXNIXAMZOZFK-UHFFFAOYSA-N
|
DB17175
| null |
Adenovirus/PNP
| null | null |
Ad/PNP | Ad/PNP/F-araAMP | adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene
| null |
DB17176
| null |
L-Leucyl-L-prolyl-L-prolyl-L-seryl-L-arginine
|
120484-65-3
|
HFL33E395I
|
H-Leu-Pro-Pro-Ser-Arg-OH | L-arginine, l-leucyl-l-prolyl-l-prolyl-l-seryl- | L-Leucyl-L-prolyl-L-prolyl-L-seryl-L-arginine | Lymphocyte Activating Pentapeptide
| null |
DB17177
| null |
Ad-RTS-hIL-12
| null | null |
Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
| null |
DB17178
| null |
Tasadenoturev
|
1448774-00-2
|
79ME7DT193
|
Ad5-DNX-2401 | adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma | Delta-24-RGD | Delta-24-RGD-4C | Delta24-RGD | Tumor-selective delta-24 ,rgd modified adenovirus serotype 5
| null |
DB17179
| null |
Olafertinib
| null |
708TLB8J3Y
|
N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide
| null |
DB17180
| null |
KX-2361
|
897016-26-1
|
RVW387BA9U
|
2-pyridineacetamide, n-((3-fluorophenyl)methyl)-5-(4-(4-morpholinyl)phenyl)- | N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) acetamide
|
CMKKPJNMYLOUCE-UHFFFAOYSA-N
|
DB17181
| null |
Ad-ISF35
| null | null |
Ad-CD154 | Ad-CD40L ISF35 | Ad-ISF35 transduced CLL B-cells | Adenovirus encoding the recombinant CD40 ligand | Adenovirus-CD 154 | Immune Stimulatory Factor 35 | rAd.CD40L
| null |
DB17182
| null |
ETBX-041
| null | null |
Ad5 [E1-, E2b-]-E6/E7 | Ad5 [E1-, E2b-]-E6∆/E7∆ | Non-oncogenic HPV 16 E6/E7
| null |
DB17183
| null |
Ad-SGE-REIC
| null | null |
Ad5-SGE-REIC/Dkk-3 | adenovirus vaccine encoding reduced expression in immortalized cell protein | REIC/Dkk-3 gene therapy
| null |
DB17184
| null |
Algenpantucel-L
| null |
I6HAD3HP89
|
Alpha (1,3) galactosyltransferase tumor vaccine | Alpha-1,3-galactosyltransferase-expressing allogeneic pancreatic tumor cell vaccine | Hyperacute pancreatic cancer vaccine | Hyperacute-pancreas immunotherapy
| null |
DB17185
| null |
Azercabtagene zapreleucel
| null |
PFZ3AP93TA
|
Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati | allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells | Allogeneic gene-edited CD19-directed CAR T cells/azercabtagene zapreleucel
| null |
DB17186
| null |
Carlecortemcel-L
| null | null |
Allogeneic ex vivo expanded umbilical cord blood cells
| null |
DB17187
| null |
GTA002
| null | null |
Allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells | Allogeneic UCB-NK cells
| null |
DB17188
| null |
PBCAR269A
| null | null |
Allogeneic gene edited BCMA-directed CAR T cells
| null |
DB17189
| null |
PBCAR20A
| null | null |
Allogeneic anti-CD20 CAR T cells | Allogeneic gene edited CD20-directed CAR (Chimeric Antigen Receptor) T cells
| null |
DB17190
| null |
CE-VST01-JC
| null | null |
Allogeneic JC polyomavirus-specific T-cell therapy | CE-VST-01-JC
| null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.